Cas:15728-05-9 3-(4-nitro-1,3-dioxoisoindol-2-yl)propanoate manufacturer & supplier

Chemical Name:3-(4-nitro-1,3-dioxoisoindol-2-yl)propanoate

CAS.NO:15728-05-9

Synonyms:3-(4-Nitro-1,3-dioxo-isoindol-2-yl)propanoate;3-nitro-N-(2-carboxyethyl)phthalimide;3-(3-nitrophthalimido)propionic acid

Molecular Formula:C₁₁H₇N₂O₆

Molecular Weight:263.18300

HS Code:2925190090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:522.5ºC at 760mmHg

Density:1.619g/cm3

Index of Refraction:

PSA:123.33000

Exact Mass:263.03000

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-(4-Nitro-1,3-dioxo-isoindol-2-yl)propanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(3-nitrophthalimido)propionic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(4-Nitro-1,3-dioxo-isoindol-2-yl)propanoate Use and application,3-nitro-N-(2-carboxyethyl)phthalimide technical grade,usp/ep/jp grade.

Related News: Dr. John K. Westwick, CEO of Resonant, added ��Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates. 3-(4-nitro-1,3-dioxoisoindol-2-yl)propanoate manufacturer The third-to-market BTK inhibitor is also looking to report top-line results from a front-line trial later this year. Imbruvica could feel more pressure if that study also turns out successful. 3-(4-nitro-1,3-dioxoisoindol-2-yl)propanoate supplier In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. 3-(4-nitro-1,3-dioxoisoindol-2-yl)propanoate vendor This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement. 3-(4-nitro-1,3-dioxoisoindol-2-yl)propanoate factory Dr. John K. Westwick, CEO of Resonant, added ��Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.